Dan Werb, PhD, is an epidemiologist and policy analyst with expertise in Human Immunodeficiency Virus (HIV), addictions, and drug policy. Dr. Werb is a Research Scientist at the Li Ka Shing Knowledge Institute (LKSKI) at St. Michael’s Hospital in Toronto. He is also an Assistant Professor in the Division of Global Public Health at the University of California, San Diego, where he is Principal Investigator of PRIMER: Preventing Injecting by Modifying Existing Responses, a five-year multi-site cohort study tasked with developing interventions to preventing entry into injection drug use. This study is funded through the inaugural United States National Institute on Drug Abuse Avenir Award, a USD$1.5 million research grant for creative new investigators proposing highly innovative research at the intersection of HIV and substance use. At the LKSKI, Dr. Werb is Director and Scientific Board Chair of the International Centre for Science in Drug Policy (ICSDP; www.icsdp.org), a recognized global leader in cutting edge policy research and communications. Dr. Werb has published dozens of studies on issues related to health policy and addictions, with a focus on preventing the transition of street youth into injection drug use, as well as on identifying the impact of policy and public health interventions on street-based drug-using populations. At the ICSDP, Dr. Werb is a sought after source of expertise on drug policy, and has appeared in media related to his work in every global hemisphere. He has helped oversee communications campaigns around such high profile projects as the Vienna Declaration (www.viennadeclaration.com). He has also published extensively on global drug policy and HIV policy. Dr. Werb is a former Trudeau Foundation Scholar and a Canadian Institutes of Health Research postdoctoral fellow. He conducts extensive knowledge translation on drug policy and public health, through print and radio journalism, and is the winner of a 2014 Canadian National Magazine Award for his popular science writing.